Skip to main content
Top
Published in: Drugs in R&D 4/2017

Open Access 01-12-2017 | Original Research Article

The Adherence Rate Threshold is Drug Specific

Authors: Melissa E. Stauffer, Paul Hutson, Anna S. Kaufman, Alan Morrison

Published in: Drugs in R&D | Issue 4/2017

Login to get access

Abstract

Introduction

Patient adherence to a medication regimen is usually expressed as an adherence rate, defined as the proportion of prescribed doses actually taken. An adherence rate threshold, above which the therapeutic effect is maintained, is typically assigned an arbitrary value, commonly 0.8.

Objective

Here, we determined the value of the adherence rate threshold objectively in different drugs of the same class, using statins as an example.

Methods

We used pharmacokinetic/pharmacodynamic (PK/PD) modeling to predict serum levels of low-density lipoprotein cholesterol (LDL-C) in patients taking simvastatin 20 mg or atorvastatin 5 mg once daily for 30 days. LDL-C reduction was modeled for adherence rates of 1.0, 0.8, 0.6, 0.4, and 0.2. The results were expressed as the percentage of time spent at the LDL-C goal (< 70 mg/dL). The adherence rate threshold was defined as the minimum adherence rate that resulted in the same amount of time at goal as perfect adherence (i.e., a rate of 1.0).

Results

For simvastatin, an adherence rate of 0.8 resulted in a significant decrease in time at the LDL-C goal compared to perfect adherence (54.8% versus 85.1%; P < 0.001), and rates < 0.8 resulted in progressively less time at goal. For atorvastatin, the rates of 0.8 and 0.6 resulted in essentially the same amount of time at goal as perfect adherence (87.8% and 87.7%, respectively, versus 88.1%; P > 0.05 for both), with less time at goal only occurring at rates ≤ 0.4 (P < 0.001). Thus, the adherence rate thresholds are > 0.8 for simvastatin and between 0.4 and 0.6 for atorvastatin.

Conclusion

These results indicate that a value of 0.8 cannot be applied universally.
Literature
2.
go back to reference Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105–16.CrossRefPubMed Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105–16.CrossRefPubMed
3.
go back to reference Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15:565–74. doi:10.1002/pds.1230 (discussion 575–67).CrossRefPubMed Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15:565–74. doi:10.​1002/​pds.​1230 (discussion 575–67).CrossRefPubMed
4.
go back to reference Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81:1013–22. doi:10.4065/81.8.1013.CrossRefPubMed Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81:1013–22. doi:10.​4065/​81.​8.​1013.CrossRefPubMed
11.
go back to reference D’Argenio D, Schumitzky A, Wang X. ADAPT 5 user’s guide: pharmacokinetic/pharmacodynamic systems analysis software. Los Angeles: Biomedical Simulations Resource; 2009. D’Argenio D, Schumitzky A, Wang X. ADAPT 5 user’s guide: pharmacokinetic/pharmacodynamic systems analysis software. Los Angeles: Biomedical Simulations Resource; 2009.
13.
go back to reference Kim J, Ahn BJ, Chae HS, Han S, Doh K, Choi J, Jun YK, Lee YW, Yim DS. A population pharmacokinetic-pharmacodynamic model for simvastatin that predicts low-density lipoprotein-cholesterol reduction in patients with primary hyperlipidaemia. Basic Clin Pharmacol Toxicol. 2011;109:156–63. doi:10.1111/j.1742-7843.2011.00700.x.CrossRefPubMed Kim J, Ahn BJ, Chae HS, Han S, Doh K, Choi J, Jun YK, Lee YW, Yim DS. A population pharmacokinetic-pharmacodynamic model for simvastatin that predicts low-density lipoprotein-cholesterol reduction in patients with primary hyperlipidaemia. Basic Clin Pharmacol Toxicol. 2011;109:156–63. doi:10.​1111/​j.​1742-7843.​2011.​00700.​x.CrossRefPubMed
15.
go back to reference Kakara M, Nomura H, Fukae M, Gotanda K, Hirota T, Matsubayashi S, Shimomura H, Hirakawa M, Ieiri I. Population pharmacodynamic analysis of LDL-cholesterol lowering effects by statins and co-medications based on electronic medical records. Br J Clin Pharmacol. 2014;78:824–35. doi:10.1111/bcp.12405.CrossRefPubMedPubMedCentral Kakara M, Nomura H, Fukae M, Gotanda K, Hirota T, Matsubayashi S, Shimomura H, Hirakawa M, Ieiri I. Population pharmacodynamic analysis of LDL-cholesterol lowering effects by statins and co-medications based on electronic medical records. Br J Clin Pharmacol. 2014;78:824–35. doi:10.​1111/​bcp.​12405.CrossRefPubMedPubMedCentral
16.
go back to reference Aoyama T, Omori T, Watabe S, Shioya A, Ueno T, Fukuda N, Matsumoto Y. Pharmacokinetic/pharmacodynamic modeling and simulation of rosuvastatin using an extension of the indirect response model by incorporating a circadian rhythm. Biol Pharm Bull. 2010;33:1082–7.CrossRefPubMed Aoyama T, Omori T, Watabe S, Shioya A, Ueno T, Fukuda N, Matsumoto Y. Pharmacokinetic/pharmacodynamic modeling and simulation of rosuvastatin using an extension of the indirect response model by incorporating a circadian rhythm. Biol Pharm Bull. 2010;33:1082–7.CrossRefPubMed
18.
go back to reference Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Z, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL, Authors/Task Force M, Additional C. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37:2999–3058. doi:10.1093/eurheartj/ehw272.CrossRefPubMed Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Z, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL, Authors/Task Force M, Additional C. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37:2999–3058. doi:10.​1093/​eurheartj/​ehw272.CrossRefPubMed
19.
go back to reference Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, American Collegeof Cardiology/American Heart Association Task Force on Practice G. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889–934. doi:10.1016/j.jacc.2013.11.002.CrossRefPubMed Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, American Collegeof Cardiology/American Heart Association Task Force on Practice G. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889–934. doi:10.​1016/​j.​jacc.​2013.​11.​002.CrossRefPubMed
20.
go back to reference Gieschke R, Steimer JL. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development. Eur J Drug Metab Pharmacokinet. 2000;25:49–58.CrossRefPubMed Gieschke R, Steimer JL. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development. Eur J Drug Metab Pharmacokinet. 2000;25:49–58.CrossRefPubMed
21.
go back to reference Smith DA, Jones B. Variability in drug response as a factor in drug design. Curr Opin Drug Discov Dev. 1999;2:33–41. Smith DA, Jones B. Variability in drug response as a factor in drug design. Curr Opin Drug Discov Dev. 1999;2:33–41.
25.
go back to reference Maclean R, Pfister M, Zhou Z, Roy A, Tuomari VA, Heifets M. Quantifying the impact of nonadherence patterns on exposure to oral immunosuppressants. Ther Clin Risk Manag. 2011;2011:149–56.CrossRef Maclean R, Pfister M, Zhou Z, Roy A, Tuomari VA, Heifets M. Quantifying the impact of nonadherence patterns on exposure to oral immunosuppressants. Ther Clin Risk Manag. 2011;2011:149–56.CrossRef
31.
go back to reference Jafari M, Ebrahimi R, Ahmadi-Kashani M, Balian H, Bashir M. Efficacy of alternate-day dosing versus daily dosing of atorvastatin. J Cardiovasc Pharmacol Ther. 2003;8:123–6.CrossRefPubMed Jafari M, Ebrahimi R, Ahmadi-Kashani M, Balian H, Bashir M. Efficacy of alternate-day dosing versus daily dosing of atorvastatin. J Cardiovasc Pharmacol Ther. 2003;8:123–6.CrossRefPubMed
32.
go back to reference Matalka MS, Ravnan MC, Deedwania PC. Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The alternate day versus daily dosing of atorvastatin study (ADDAS). Am Heart J. 2002;144:674–7.CrossRefPubMed Matalka MS, Ravnan MC, Deedwania PC. Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The alternate day versus daily dosing of atorvastatin study (ADDAS). Am Heart J. 2002;144:674–7.CrossRefPubMed
36.
go back to reference Itoh T, Matsumoto M, Hougaku H, Handa N, Tsubakihara Y, Yamada Y, Imaizumi M, Hoshi M, Shimazu Y, Hori M, Kawamori R, Ueda N, Fusamoto H, Kamada T. Effects of low-dose simvastatin therapy on serum lipid levels in patients with moderate hypercholesterolemia: a 12-month study. The Simvastatin Study Group. Clin Ther. 1997;19:487–97.CrossRefPubMed Itoh T, Matsumoto M, Hougaku H, Handa N, Tsubakihara Y, Yamada Y, Imaizumi M, Hoshi M, Shimazu Y, Hori M, Kawamori R, Ueda N, Fusamoto H, Kamada T. Effects of low-dose simvastatin therapy on serum lipid levels in patients with moderate hypercholesterolemia: a 12-month study. The Simvastatin Study Group. Clin Ther. 1997;19:487–97.CrossRefPubMed
37.
go back to reference Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, Schneck D. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005;78:330–41. doi:10.1016/j.clpt.2005.06.013.CrossRefPubMed Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, Schneck D. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005;78:330–41. doi:10.​1016/​j.​clpt.​2005.​06.​013.CrossRefPubMed
38.
go back to reference Wu CC, Sy R, Tanphaichitr V, Hin AT, Suyono S, Lee YT. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein–cholesterol—a multinational, multicenter, double-blind study. J Formos Med Assoc. 2002;101:478–87.PubMed Wu CC, Sy R, Tanphaichitr V, Hin AT, Suyono S, Lee YT. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein–cholesterol—a multinational, multicenter, double-blind study. J Formos Med Assoc. 2002;101:478–87.PubMed
Metadata
Title
The Adherence Rate Threshold is Drug Specific
Authors
Melissa E. Stauffer
Paul Hutson
Anna S. Kaufman
Alan Morrison
Publication date
01-12-2017
Publisher
Springer International Publishing
Published in
Drugs in R&D / Issue 4/2017
Print ISSN: 1174-5886
Electronic ISSN: 1179-6901
DOI
https://doi.org/10.1007/s40268-017-0216-6

Other articles of this Issue 4/2017

Drugs in R&D 4/2017 Go to the issue